克罗恩病患儿英夫利西单抗维持治疗前血药浓度与疾病转归的关系

doi:10.7499/j.issn.1008-8830.2205181

Abstract
Figure/Table
References(21)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (607 KB) HTML
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To study the association between infliximab trough level (IFX-TL) prior to maintenance treatment and disease outcome in children with Crohn's disease (CD). Methods A retrospective analysis was performed on 35 children with CD who received induction therapy with infliximab (IFX) and the measurement of IFX-TL before maintenance treatment from August 2018 to November 2021. Clinical data and laboratory markers at baseline and before maintenance treatment were collected, and the association between outcome and IFX-TL was analyzed. Results The clinical remission group, endoscopic remission group, and combined remission group had a significantly higher IFX-TL level than the corresponding non-remission groups (P<0.05), and there was no significant difference in the IFX-TL level between the biological remission and non-biological remission groups (P>0.05). The receiver operating characteristic (ROC) curve showed that IFX-TL had an area under the ROC curve of 0.959 (95%CI: 0.894-1) in predicting clinical remission, with a sensitivity of 90% and a specificity of 100% at the optimal cutoff value of 2.3 μg/mL (P<0.001). Conclusions Among children with CD receiving infliximab induction therapy, the children achieving clinical and endoscopic remission before maintenance treatment tend to have a higher level of IFX-TL. IFX-TL has a certain predictive value for clinical remission.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Xing
	YU Yi
	WANG Xin-Qiong
	LI Jia
	XU Xu
	XU Chun-Di
	XIAO Yuan

Key words： Crohn's disease Infliximab Therapeutic drug monitoring Pediatric Crohn's disease activity index Simple Endoscopic Score for Crohn's disease Child

Received: 02 June 2022

Cite this article:

DENG Xing,YU Yi,WANG Xin-Qiong et al. Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease[J]. CJCP, 2022, 24(11): 1246-1251.

URL:

http://www.zgddek.com/EN/10.7499/j.issn.1008-8830.2205181 OR http://www.zgddek.com/EN/Y2022/V24/I11/1246

	Wang XQ, Zhang Y, Xu CD, et al. Inflammatory bowel disease in Chinese children: a multicenter analysis over a decade from Shanghai[J]. Inflamm Bowel Dis, 2013, 19(2): 423-428. PMID: 23340680. DOI: 10.1097/MIB.0b013e318286f9f2.
	中华医学会儿科学分会消化学组, 中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019, 57(7): 501-507. PMID: 31269548. DOI: 10.3760/cma.j.issn.0578‐1310.2019.07.002.
	3 中华医学会消化病学分会炎症性肠病学组儿科协作组. 抗肿瘤坏死因子-α单克隆抗体治疗儿童克罗恩病的专家共识[J]. 中华炎性肠病杂志, 2021, 5(2): 114-124. DOI: 10.3760/cma.j.cn101480-20210105-00001.
	van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2021, 15(2): 171-194. PMID: 33026087. DOI: 10.1093/ecco-jcc/jjaa161.
	van Hoeve K, Seyed Tabib NS, Dreesen E, et al. Infliximab concentrations during induction are predictive for endoscopic remission in pediatric patients with inflammatory bowel disease under combination therapy[J]. J Pediatr, 2022, 240: 150-157.e4. PMID: 34481805. DOI: 10.1016/j.jpeds.2021.08.079.
	van Hoeve K, Dreesen E, Hoffman I, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease[J]. J Crohns Colitis, 2018, 12(11): 1316-1325. PMID: 30239644. DOI: 10.1093/ecco-jcc/jjy111.
	Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial[J]. Gut, 2014, 63(11): 1721-1727. PMID: 24474383. PMCID: PMC4215276. DOI: 10.1136/gutjnl-2012-304094.
	GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1): 17-30. PMID: 31648971. PMCID: PMC7026709. DOI: 10.1016/S2468-1253(19)30333-4.
	Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification[J]. Inflamm Bowel Dis, 2011, 17(6): 1314-1321. PMID: 21560194. DOI: 10.1002/ibd.21493.
	Zubin G, Peter L. Predicting endoscopic Crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin[J]. Inflamm Bowel Dis, 2015, 21(6): 1386-1391. PMID: 25851564. PMCID: PMC4450968. DOI: 10.1097/MIB.0000000000000388.
	Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD[J]. Gastrointest Endosc, 2004, 60(4): 505-512. PMID: 15472670. DOI: 10.1016/S0016-5107(04)01878-4.
	Barber GE, Yajnik V, Khalili H, et al. Genetic markers predict primary non-response and durable response to anti-TNF biologic therapies in Crohn's disease[J]. Am J Gastroenterol, 2016, 111(12): 1816-1822. PMID: 27596696. PMCID: PMC5143156. DOI: 10.1038/ajg.2016.408.
	Moore H, Dolce P, Devas N, et al. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis[J]. United European Gastroenterol J, 2020, 8(4): 425-435. PMID: 32213038. PMCID: PMC7226697. DOI: 10.1177/2050640620912877.
	Hemperly A, Vande Casteele N. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease[J]. Clin Pharmacokinet, 2018, 57(8): 929-942. PMID: 29330783. DOI: 10.1007/s40262-017-0627-0.
	Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 341-353. PMID: 30824404. DOI: 10.1016/S2468-1253(19)30012-3.
	Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors[J]. Aliment Pharmacol Ther, 2017, 46(2): 150-161. PMID: 28481014. DOI: 10.1111/apt.14124.
	Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease[J]. Clin Gastroenterol Hepatol, 2015, 13(3): 539-547.e2. PMID: 25245629. DOI: 10.1016/j.cgh.2014.09.031.
	Colman RJ, Tsai YT, Jackson K, et al. Achieving target infliximab drug concentrations improves blood and fecal neutrophil biomarkers in Crohn's disease[J]. Inflamm Bowel Dis, 2021, 27(7): 1045-1051. PMID: 32944769. PMCID: PMC8205636. DOI: 10.1093/ibd/izaa241.
	Hoekman DR, Brandse JF, de Meij TG, et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease[J]. Scand J Gastroenterol, 2015, 50(9): 1110-1117. PMID: 25865965. DOI: 10.3109/00365521.2015.1027264.
	Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease[J]. J Crohns Colitis, 2013, 7(9): 736-743. PMID: 23200919. DOI: 10.1016/j.crohns.2012.10.019.
	Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015, 148(7): 1320-1329.e3. PMID: 25724455. DOI: 10.1053/j.gastro.2015.02.031.